Compared with other classified subtypes, ER/PR−, ER−/PR−, or ER+/PR−, ER/PR+ tumors are the most responsive to endocrine therapy due to the characteristics of hormone-dependent growth retained by the tumor cells. This evidence concerns the gene PGR and neoplasm.